Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W D Figg

Showing results (101-110 of 135) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigmW H Wilson, L Sorbara, W D Figg, et al.
Muscle & Nerve|July 6, 2001
Thalidomide neuropathy in patients treated for metastatic prostate cancerF M Molloy, M K Floeter, N A Syed, et al.
Cancer Research|April 1, 1994
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancerA Thibault, M R Cooper, W D Figg, et al.
Cancer|August 1, 1995
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variablesN A Dawson, M R Cooper, W D Figg, et al.
Cancer|December 18, 2001
A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar)S Bates, M Kang, B Meadows, et al.
Clinical Pharmacology and Therapeutics|April 1, 2011
Effect of ABCC2 (MRP2) transport function on erythromycin metabolismR M Franke, C S Lancaster, C J Peer, et al.
Biopharmaceutics & Drug Disposition|May 1, 1997
Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatinW D Figg, M C Christian, R Lush, et al.
Microvascular Research|June 30, 2000
Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesisA C Berger, H R Alexander, G Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1996
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancerA Thibault, D Samid, A C Tompkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomasH A Fine, W D Figg, K Jaeckle, et al.
Pageof 14

Showing results (101-110 of 135) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigmW H Wilson, L Sorbara, W D Figg, et al.
Muscle & Nerve|July 6, 2001
Thalidomide neuropathy in patients treated for metastatic prostate cancerF M Molloy, M K Floeter, N A Syed, et al.
Cancer Research|April 1, 1994
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancerA Thibault, M R Cooper, W D Figg, et al.
Cancer|August 1, 1995
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variablesN A Dawson, M R Cooper, W D Figg, et al.
Cancer|December 18, 2001
A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar)S Bates, M Kang, B Meadows, et al.
Clinical Pharmacology and Therapeutics|April 1, 2011
Effect of ABCC2 (MRP2) transport function on erythromycin metabolismR M Franke, C S Lancaster, C J Peer, et al.
Biopharmaceutics & Drug Disposition|May 1, 1997
Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatinW D Figg, M C Christian, R Lush, et al.
Microvascular Research|June 30, 2000
Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesisA C Berger, H R Alexander, G Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1996
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancerA Thibault, D Samid, A C Tompkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomasH A Fine, W D Figg, K Jaeckle, et al.
Pageof 14